FCHS Launches $12M Offering, Reverse Split, CEO Cedes Super-Voting Control

Ticker: FCHS · Form: S-1/A · Filed: Dec 30, 2025 · CIK: 1416876

Sentiment: bearish

Topics: S-1/A, Preferred Stock Offering, Warrants, Reverse Stock Split, Dilution Risk, Corporate Governance, Capital Raise

Related Tickers: FCHS

TL;DR

**FCHS is making a desperate play for capital with a dilutive preferred stock offering and a massive reverse split, but shedding super-voting shares is a small win for governance.**

AI Summary

First Choice Healthcare Solutions, Inc. (FCHS) is undertaking a firm commitment public offering of 2,400,000 shares of Series D Convertible Preferred Stock and accompanying Warrants to purchase an equal number of Series D Preferred Stock, aiming to raise $12,000,000 at a public offering price of $5.00 per share and warrant. After underwriting discounts of $960,000 (8% of the offering), the company expects net proceeds of $11,040,000 before other expenses. The offering includes up to 8,124,000 shares of common stock issuable upon conversion of the Series D Preferred Stock and payment of dividends. A significant corporate change involves a proposed 1-for-2,000 reverse stock split of its 32,958,288 outstanding common shares, which will occur after the registration statement's effectiveness but before NYSE listing. Furthermore, the 4 outstanding shares of Series A Super Voting Preferred Stock held by CEO Lance Friedman will be cancelled, eliminating his super-voting control. The company also faces risks from anti-dilution provisions in the Series D Preferred Stock, which could lead to significant dilution if future securities are issued below the initial $5 conversion price, potentially requiring an increase in authorized shares.

Why It Matters

This S-1/A filing signals a critical capital raise for First Choice Healthcare Solutions, Inc., aiming to inject $11.04 million into the company. The proposed 1-for-2,000 reverse stock split is a strategic move to potentially meet listing requirements for a national exchange, which could improve liquidity and investor perception. The cancellation of CEO Lance Friedman's Series A Super Voting Preferred Stock fundamentally alters corporate governance, shifting FCHS away from a 'controlled company' structure and potentially increasing investor influence. However, the anti-dilution provisions in the Series D Preferred Stock pose a substantial risk of future dilution for existing common shareholders, impacting long-term value.

Risk Assessment

Risk Level: high — The offering involves a high degree of risk due to significant potential dilution from the Series D Convertible Preferred Stock's anti-dilution provisions, which mandate a lower conversion price if future securities are issued below $5 per share. The company explicitly states, "as there is no floor price on the Conversion Price, we cannot determine the total number of shares issuable upon conversion." This uncertainty, coupled with the possibility of not having sufficient authorized shares for conversion, presents a substantial risk to existing shareholders.

Analyst Insight

Investors should exercise extreme caution and thoroughly evaluate the potential for significant dilution from the Series D Convertible Preferred Stock's anti-dilution provisions. Given the lack of a floor price on the conversion, investors should consider the worst-case dilution scenarios and the company's ability to secure additional authorized shares if needed, before making any investment decisions.

Key Numbers

Key Players & Entities

FAQ

What is First Choice Healthcare Solutions, Inc. offering in its S-1/A filing?

First Choice Healthcare Solutions, Inc. is offering 2,400,000 shares of Series D Convertible Preferred Stock and 2,400,000 Warrants to purchase Series D Preferred Stock, with an assumed combined public offering price of $5.00 per share and warrant.

How much capital does FCHS expect to raise from this offering?

FCHS expects to raise gross proceeds of $12,000,000 from the offering. After deducting underwriting discounts of $960,000, the company anticipates net proceeds of $11,040,000 before other offering expenses.

What is the impact of the proposed reverse stock split on FCHS shares?

FCHS plans a 1-for-2,000 reverse stock split on its 32,958,288 outstanding common shares. This will reduce the number of outstanding common shares and is intended to occur after the registration statement's effectiveness but prior to listing on the NYSE.

How will the Series D Convertible Preferred Stock affect FCHS's common stock?

The Series D Convertible Preferred Stock is convertible into common stock at an assumed initial conversion price of $5 per share. The offering registers up to 8,124,000 shares of common stock, representing potential dilution from conversions and dividend payments.

What are the key risks associated with the Series D Convertible Preferred Stock for FCHS investors?

A primary risk is the anti-dilution provision, which requires lowering the conversion price if FCHS issues future securities below $5 per share. This could lead to a significantly greater number of common shares being issued upon conversion, causing substantial dilution to existing shareholders.

What changes are occurring in FCHS's corporate governance?

Lance Friedman, the CEO, will have his 4 outstanding shares of Series A Super Voting Preferred Stock cancelled upon completion of the offering. This eliminates his super-voting control and means FCHS will not be a 'controlled company' under NYSE American standards.

Are there other shares being offered concurrently with the FCHS IPO?

Yes, concurrently with the IPO, selling stockholders are offering up to 720,000 shares of common stock through a Resale Prospectus. This includes 51,114 shares issuable upon the exercise of certain outstanding warrants.

What is the role of RBW Capital Partners LLC in the FCHS offering?

RBW Capital Partners LLC, acting through Dawson James Securities, Inc., is the representative of the underwriters for the firm commitment public offering. They are responsible for managing the sale of the Series D Convertible Preferred Stock and Warrants.

Will the Series D Convertible Preferred Stock or Warrants be listed on an exchange?

No, First Choice Healthcare Solutions, Inc. does not intend to apply for a listing of the Series D Convertible Preferred Stock or the Warrants on any securities exchange or other nationally recognized trading system, which will limit their liquidity.

What is the potential impact if FCHS's conversion price drops significantly?

If the conversion price drops significantly due to anti-dilution provisions, FCHS may not have sufficient authorized shares to satisfy conversions. This would require increasing authorized shares, which could be time-consuming and expensive, and further depress the common stock price.

Risk Factors

Industry Context

First Choice Healthcare Solutions is pivoting into the primary care and wellness clinic sector, focusing on life improvement services like anti-aging, weight management, and hormone replacement, alongside pharmacy services. This market is characterized by increasing demand for preventative and personalized healthcare solutions, driven by an aging population and growing consumer interest in wellness. The competitive landscape includes established healthcare providers, specialized clinics, and emerging direct-to-consumer health tech companies.

Regulatory Implications

The company's shift to primary care and wellness clinics may subject it to a different set of healthcare regulations, including those related to patient privacy (HIPAA), licensing, and potentially state-specific regulations for medical practices and pharmacies. Compliance with these evolving regulatory frameworks will be critical for operational success and avoiding penalties.

What Investors Should Do

  1. Carefully evaluate the dilution risk associated with the Series D Preferred Stock's anti-dilution provisions.
  2. Assess the execution risk of the company's strategic pivot to primary care and wellness clinics.
  3. Monitor the impact of the proposed 1-for-2,000 reverse stock split on share price and market perception.
  4. Understand the implications of the CEO's loss of super-voting control.

Glossary

Series D Convertible Preferred Stock
A class of preferred stock that can be converted into a specified number of common stock shares under certain conditions, often at the holder's option or upon a triggering event. (This is the primary security being offered in the current public offering, representing a significant portion of the capital being raised and carrying potential future dilution.)
Warrants
A type of derivative that gives the holder the right, but not the obligation, to buy or sell a security (like stock) at a specified price (the exercise price) on or before a certain date. (These are offered alongside the Series D Preferred Stock, providing an additional potential source of capital for the company if exercised and representing further potential dilution.)
Firm Commitment Public Offering
An underwriting arrangement where the investment bank(s) purchase all of the securities from the issuer at a set price and then resell them to the public, assuming the risk of unsold shares. (This indicates the underwriters are committed to purchasing the $12,000,000 in securities, providing a high degree of certainty for the company regarding the capital raised, subject to underwriting discounts.)
Reverse Stock Split
A corporate action where a company reduces the total number of its outstanding shares by consolidating existing shares into fewer, proportionally more valuable shares. (FCHS is proposing a 1-for-2,000 reverse stock split to meet listing requirements, which will significantly reduce the number of outstanding common shares.)
Anti-Dilution Provisions
Clauses in preferred stock agreements designed to protect investors from a decrease in the value of their investment due to the issuance of new stock by the company at a lower price than previously paid. (These provisions in the Series D Preferred Stock pose a significant risk of dilution to existing common shareholders if the company issues new equity below the $5.00 conversion price.)
Super Voting Preferred Stock
A class of preferred stock that carries voting rights disproportionately greater than its economic interest, often used to maintain control. (The cancellation of the Series A Super Voting Preferred Stock held by the CEO will eliminate concentrated voting control, changing the company's governance structure.)

Year-Over-Year Comparison

This S-1/A filing represents a significant strategic shift for First Choice Healthcare Solutions, Inc., detailing a pivot away from its historic orthopedic business towards primary care and wellness clinics. Consequently, direct year-over-year comparisons of operational metrics like revenue and margins are not applicable as the company is essentially repositioning itself. The filing primarily focuses on the proposed offering of Series D Convertible Preferred Stock and Warrants, the associated capital raise of $12,000,000, and significant corporate restructuring including a reverse stock split and the cancellation of super-voting stock, rather than reporting on past performance.

Filing Stats: 4,655 words · 19 min read · ~16 pages · Grade level 17.8 · Accepted 2025-12-30 16:18:18

Key Financial Figures

Filing Documents

Underwriting

Underwriting discounts and commissions (3) $ 0.40 $ 960,000 Proceeds to us (before expenses) $ 4.60 $ 11,040,000 (1) The per share price represents the combined public offering price for one share of Offered Preferred Stock and a Warrant to purchase one share of common stock. The price of a share of the Offered Preferred Stock and accompanying Warrant in this prospectus assumes a combined public offering price of $5 per share and accompanying Warrant and a conversion price and exercise price per share of the Offered Preferred Stock and per Warrant of $5 per share, as the case may be. (2) Assumes no exercise of the over-allotment option to purchase units we have granted to the underwriters as described below. See "Underwriting" on page 73 for a description of total compensation payable to the underwriters. (3) Does not include a reasonable and accountable out-of-pocket expenses not exceeding $75,000 payable to RBW Capital Partners LLC acting through Dawson James Securities, Inc. (the "Representative"), the representative of the underwriters. See "Underwriting" on page 73 for a description of compensation payable to the underwriters. We have granted the underwriters a 45-day option to purchase from us, at the public offering price, less the underwriting discounts, up to 360,000 additional shares of Offered Preferred Stock and/or Warrants to purchase up to 360,000 shares of Warrant Preferred Stock, solely to cover over-allotments, if any. This offering also relates to the additional shares of Offered Preferred Stock and Warrants to purchase shares of Warrant Preferred Stock, issuable upon exercise of the over-allotment option, if any, the common shares issuable upon the exercise of such Offered Preferred Stock and such Warrant Preferred Stock and the shares of common stock issuable upon payment of any dividends accrued on such Offered Preferred Stock and such Warrant Preferred Stock. Unless otherwise noted, the share and per share information in this

DILUTION

DILUTION 32 DESCRIPTION OF CAPITAL STOCK 33 MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS 36

BUSINESS

BUSINESS 47 MANAGEMENT 62 EXECUTIVE COMPENSATION 64 CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS 65 SECURITY 65 SHARES ELIGIBLE FOR FUTURE SALE 66 MATERIAL U.S. FEDERAL INCOME TAX CONSIDERATIONS 68

UNDERWRITING

UNDERWRITING 73 DETERMINATION OF OFFERING PRICE 75 INTERESTS OF NAMED EXPERTS AND COUNSEL 75 EXPERTS 75 LEGAL MATTERS 76 WHERE YOU CAN FIND ADDITIONAL INFORMATION 76 INDEX TO FINANCIAL STATEMENTS F-1 i ABOUT THIS PROSPECTUS The registration statement of which this prospectus forms a part that we filed with the Securities and Exchange Commission (the "SEC") includes exhibits that provide more detail of the matters discussed in this prospectus. You should read this prospectus and the related exhibits filed with the SEC, together with the additional information described under the headings "Where You Can Find Additional Information" before making your investment decision. You should rely only on the information provided in this prospectus, in any prospectus supplement or in a related free writing prospectus, or documents to which we otherwise refer you. In addition, this prospectus contains summaries of certain provisions contained in some of the documents described herein, but reference is made to the actual documents for complete information. This prospectus includes important information about us, the securities being offered and other information you should know before investing in our securities. You should not assume that the information contained in or incorporated by reference this prospectus is accurate on any date subsequent to the date set forth on the front cover of this prospectus, even though this prospectus is delivered or securities are sold or otherwise disposed of on a later date. It is important for you to read and consider all information contained or incorporated by reference in this prospectus in making your investment decision. All of the summaries in this prospectus are qualified in their entirety by the actual documents. Copies of some of the documents referred to herein have been filed, will be filed or will be incorporated by reference as exhibits to the registration statement of which this prospectus is a part, and

Business

Business Overview First Choice Healthcare Solutions, Inc. ("FCHS," "the Company," "we," "our" or "us") is actively engaged in pivoting the Company's strategy away from our historic orthopedic business model to a strategy of developing a national chain of innovative primary care and wellness clinics focused on providing life improvement services (anti-aging, weight management, and hormone replacement) and pharmacy services, in key high growth markets throughout the U.S. Although we still provide rehabilitative services on a limited basis, such as Physical Therapy, concurrent with the completion of this offering we will terminate all of our remaining legacy orthopedic and Physical Therapy services and focus the company resources on our strategy of building and operating primary care and wellness clinics. Operating Subsidiaries We have operated as First Choice Healthcare Solutions, Inc., a Delaware corporatio

View Full Filing

View this S-1/A filing on SEC EDGAR

View on Read The Filing